Medical Care
Global RNAi for Therapeutic Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
- Mar 24, 25
- ID: 144449
- Pages: 94
- Figures: 98
- Views: 47
The global RNAi for Therapeutic market size was US$ 358 million in 2024 and is forecast to a readjusted size of US$ 4272 million by 2031 with a CAGR of 43.1% during the forecast period 2025-2031.
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.
US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.
In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.
The global RNAi for Therapeutic market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
By Type: (Dominant Segment vs High-Margin Innovation)
siRNA
miRNA
shRNA
By Application: (Core Demand Driver vs Emerging Opportunity)
Cancer
Cardiovascular
HBV
Others
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Alnylam Pharmaceuticals in Europe)
- Emerging Product Trends: siRNA adoption vs. miRNA premiumization
- Demand-Side Dynamics: Cancer growth in China vs. Cardiovascular potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
Australia
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of RNAi for Therapeutic market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., miRNA in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Cardiovascular in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the RNAi for Therapeutic value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.
US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.
In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.
The global RNAi for Therapeutic market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
By Type: (Dominant Segment vs High-Margin Innovation)
siRNA
miRNA
shRNA
By Application: (Core Demand Driver vs Emerging Opportunity)
Cancer
Cardiovascular
HBV
Others
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Alnylam Pharmaceuticals in Europe)
- Emerging Product Trends: siRNA adoption vs. miRNA premiumization
- Demand-Side Dynamics: Cancer growth in China vs. Cardiovascular potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
Australia
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of RNAi for Therapeutic market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., miRNA in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Cardiovascular in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the RNAi for Therapeutic value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 siRNA
1.2.3 miRNA
1.2.4 shRNA
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Cancer
1.3.3 Cardiovascular
1.3.4 HBV
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global RNAi for Therapeutic Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global RNAi for Therapeutic Revenue Market Share by Region (2020-2025)
2.4 Global RNAi for Therapeutic Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America RNAi for Therapeutic Market Size and Prospective (2020-2031)
2.5.2 Europe RNAi for Therapeutic Market Size and Prospective (2020-2031)
2.5.3 China RNAi for Therapeutic Market Size and Prospective (2020-2031)
2.5.4 Japan RNAi for Therapeutic Market Size and Prospective (2020-2031)
2.5.5 Australia RNAi for Therapeutic Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global RNAi for Therapeutic Historic Market Size by Type (2020-2025)
3.2 Global RNAi for Therapeutic Forecasted Market Size by Type (2026-2031)
3.3 Different Types RNAi for Therapeutic Representative Players
4 Breakdown Data by Application
4.1 Global RNAi for Therapeutic Historic Market Size by Application (2020-2025)
4.2 Global RNAi for Therapeutic Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in RNAi for Therapeutic Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top RNAi for Therapeutic Players by Revenue (2020-2025)
5.1.2 Global RNAi for Therapeutic Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by RNAi for Therapeutic Revenue
5.4 Global RNAi for Therapeutic Market Concentration Analysis
5.4.1 Global RNAi for Therapeutic Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by RNAi for Therapeutic Revenue in 2024
5.5 Global Key Players of RNAi for Therapeutic Head office and Area Served
5.6 Global Key Players of RNAi for Therapeutic, Product and Application
5.7 Global Key Players of RNAi for Therapeutic, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America RNAi for Therapeutic Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America RNAi for Therapeutic Market Size by Type (2020-2025)
6.1.2.2 North America RNAi for Therapeutic Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America RNAi for Therapeutic Market Size by Application (2020-2025)
6.1.3.2 North America RNAi for Therapeutic Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe RNAi for Therapeutic Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe RNAi for Therapeutic Market Size by Type (2020-2025)
6.2.2.2 Europe RNAi for Therapeutic Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe RNAi for Therapeutic Market Size by Application (2020-2025)
6.2.3.2 Europe RNAi for Therapeutic Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments and Downstream
6.3.1 China RNAi for Therapeutic Revenue by Company (2020-2025)
6.3.2 China Market Size by Type
6.3.2.1 China RNAi for Therapeutic Market Size by Type (2020-2025)
6.3.2.2 China RNAi for Therapeutic Market Share by Type (2020-2025)
6.3.3 China Market Size by Application
6.3.3.1 China RNAi for Therapeutic Market Size by Application (2020-2025)
6.3.3.2 China RNAi for Therapeutic Market Share by Application (2020-2025)
6.3.4 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments and Downstream
6.4.1 Japan RNAi for Therapeutic Revenue by Company (2020-2025)
6.4.2 Japan Market Size by Type
6.4.2.1 Japan RNAi for Therapeutic Market Size by Type (2020-2025)
6.4.2.2 Japan RNAi for Therapeutic Market Share by Type (2020-2025)
6.4.3 Japan Market Size by Application
6.4.3.1 Japan RNAi for Therapeutic Market Size by Application (2020-2025)
6.4.3.2 Japan RNAi for Therapeutic Market Share by Application (2020-2025)
6.4.4 Japan Market Trend and Opportunities
6.5 Australia Market: Players, Segments and Downstream
6.5.1 Australia RNAi for Therapeutic Revenue by Company (2020-2025)
6.5.2 Australia Market Size by Type
6.5.2.1 Australia RNAi for Therapeutic Market Size by Type (2020-2025)
6.5.2.2 Australia RNAi for Therapeutic Market Share by Type (2020-2025)
6.5.3 Australia Market Size by Application
6.5.3.1 Australia RNAi for Therapeutic Market Size by Application (2020-2025)
6.5.3.2 Australia RNAi for Therapeutic Market Share by Application (2020-2025)
6.5.4 Australia Market Trend and Opportunities
7 Key Players Profiles
7.1 Alnylam Pharmaceuticals
7.1.1 Alnylam Pharmaceuticals Company Details
7.1.2 Alnylam Pharmaceuticals Business Overview
7.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Introduction
7.1.4 Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)
7.1.5 Alnylam Pharmaceuticals Recent Development
7.2 Arbutus Biopharma (Tekmira)
7.2.1 Arbutus Biopharma (Tekmira) Company Details
7.2.2 Arbutus Biopharma (Tekmira) Business Overview
7.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Introduction
7.2.4 Arbutus Biopharma (Tekmira) Revenue in RNAi for Therapeutic Business (2020-2025)
7.2.5 Arbutus Biopharma (Tekmira) Recent Development
7.3 Arrowhead
7.3.1 Arrowhead Company Details
7.3.2 Arrowhead Business Overview
7.3.3 Arrowhead RNAi for Therapeutic Introduction
7.3.4 Arrowhead Revenue in RNAi for Therapeutic Business (2020-2025)
7.3.5 Arrowhead Recent Development
7.4 Dicerna Pharmaceuticals
7.4.1 Dicerna Pharmaceuticals Company Details
7.4.2 Dicerna Pharmaceuticals Business Overview
7.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Introduction
7.4.4 Dicerna Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)
7.4.5 Dicerna Pharmaceuticals Recent Development
7.5 Mirna Therapeutics
7.5.1 Mirna Therapeutics Company Details
7.5.2 Mirna Therapeutics Business Overview
7.5.3 Mirna Therapeutics RNAi for Therapeutic Introduction
7.5.4 Mirna Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025)
7.5.5 Mirna Therapeutics Recent Development
7.6 Quark Pharmaceuticals
7.6.1 Quark Pharmaceuticals Company Details
7.6.2 Quark Pharmaceuticals Business Overview
7.6.3 Quark Pharmaceuticals RNAi for Therapeutic Introduction
7.6.4 Quark Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)
7.6.5 Quark Pharmaceuticals Recent Development
7.7 RXi Pharmaceuticals
7.7.1 RXi Pharmaceuticals Company Details
7.7.2 RXi Pharmaceuticals Business Overview
7.7.3 RXi Pharmaceuticals RNAi for Therapeutic Introduction
7.7.4 RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)
7.7.5 RXi Pharmaceuticals Recent Development
7.8 Silence Therapeutics
7.8.1 Silence Therapeutics Company Details
7.8.2 Silence Therapeutics Business Overview
7.8.3 Silence Therapeutics RNAi for Therapeutic Introduction
7.8.4 Silence Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025)
7.8.5 Silence Therapeutics Recent Development
7.9 Benitec Biopharma
7.9.1 Benitec Biopharma Company Details
7.9.2 Benitec Biopharma Business Overview
7.9.3 Benitec Biopharma RNAi for Therapeutic Introduction
7.9.4 Benitec Biopharma Revenue in RNAi for Therapeutic Business (2020-2025)
7.9.5 Benitec Biopharma Recent Development
7.10 miRagen Therapeutics
7.10.1 miRagen Therapeutics Company Details
7.10.2 miRagen Therapeutics Business Overview
7.10.3 miRagen Therapeutics RNAi for Therapeutic Introduction
7.10.4 miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025)
7.10.5 miRagen Therapeutics Recent Development
7.11 Sylentis
7.11.1 Sylentis Company Details
7.11.2 Sylentis Business Overview
7.11.3 Sylentis RNAi for Therapeutic Introduction
7.11.4 Sylentis Revenue in RNAi for Therapeutic Business (2020-2025)
7.11.5 Sylentis Recent Development
7.12 Gradalis
7.12.1 Gradalis Company Details
7.12.2 Gradalis Business Overview
7.12.3 Gradalis RNAi for Therapeutic Introduction
7.12.4 Gradalis Revenue in RNAi for Therapeutic Business (2020-2025)
7.12.5 Gradalis Recent Development
7.13 Sirnaomics
7.13.1 Sirnaomics Company Details
7.13.2 Sirnaomics Business Overview
7.13.3 Sirnaomics RNAi for Therapeutic Introduction
7.13.4 Sirnaomics Revenue in RNAi for Therapeutic Business (2020-2025)
7.13.5 Sirnaomics Recent Development
7.14 Silenseed
7.14.1 Silenseed Company Details
7.14.2 Silenseed Business Overview
7.14.3 Silenseed RNAi for Therapeutic Introduction
7.14.4 Silenseed Revenue in RNAi for Therapeutic Business (2020-2025)
7.14.5 Silenseed Recent Development
8 RNAi for Therapeutic Market Dynamics
8.1 RNAi for Therapeutic Industry Trends
8.2 RNAi for Therapeutic Market Drivers
8.3 RNAi for Therapeutic Market Challenges
8.4 RNAi for Therapeutic Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 siRNA
1.2.3 miRNA
1.2.4 shRNA
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Cancer
1.3.3 Cardiovascular
1.3.4 HBV
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global RNAi for Therapeutic Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global RNAi for Therapeutic Revenue Market Share by Region (2020-2025)
2.4 Global RNAi for Therapeutic Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America RNAi for Therapeutic Market Size and Prospective (2020-2031)
2.5.2 Europe RNAi for Therapeutic Market Size and Prospective (2020-2031)
2.5.3 China RNAi for Therapeutic Market Size and Prospective (2020-2031)
2.5.4 Japan RNAi for Therapeutic Market Size and Prospective (2020-2031)
2.5.5 Australia RNAi for Therapeutic Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global RNAi for Therapeutic Historic Market Size by Type (2020-2025)
3.2 Global RNAi for Therapeutic Forecasted Market Size by Type (2026-2031)
3.3 Different Types RNAi for Therapeutic Representative Players
4 Breakdown Data by Application
4.1 Global RNAi for Therapeutic Historic Market Size by Application (2020-2025)
4.2 Global RNAi for Therapeutic Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in RNAi for Therapeutic Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top RNAi for Therapeutic Players by Revenue (2020-2025)
5.1.2 Global RNAi for Therapeutic Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by RNAi for Therapeutic Revenue
5.4 Global RNAi for Therapeutic Market Concentration Analysis
5.4.1 Global RNAi for Therapeutic Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by RNAi for Therapeutic Revenue in 2024
5.5 Global Key Players of RNAi for Therapeutic Head office and Area Served
5.6 Global Key Players of RNAi for Therapeutic, Product and Application
5.7 Global Key Players of RNAi for Therapeutic, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America RNAi for Therapeutic Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America RNAi for Therapeutic Market Size by Type (2020-2025)
6.1.2.2 North America RNAi for Therapeutic Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America RNAi for Therapeutic Market Size by Application (2020-2025)
6.1.3.2 North America RNAi for Therapeutic Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe RNAi for Therapeutic Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe RNAi for Therapeutic Market Size by Type (2020-2025)
6.2.2.2 Europe RNAi for Therapeutic Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe RNAi for Therapeutic Market Size by Application (2020-2025)
6.2.3.2 Europe RNAi for Therapeutic Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments and Downstream
6.3.1 China RNAi for Therapeutic Revenue by Company (2020-2025)
6.3.2 China Market Size by Type
6.3.2.1 China RNAi for Therapeutic Market Size by Type (2020-2025)
6.3.2.2 China RNAi for Therapeutic Market Share by Type (2020-2025)
6.3.3 China Market Size by Application
6.3.3.1 China RNAi for Therapeutic Market Size by Application (2020-2025)
6.3.3.2 China RNAi for Therapeutic Market Share by Application (2020-2025)
6.3.4 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments and Downstream
6.4.1 Japan RNAi for Therapeutic Revenue by Company (2020-2025)
6.4.2 Japan Market Size by Type
6.4.2.1 Japan RNAi for Therapeutic Market Size by Type (2020-2025)
6.4.2.2 Japan RNAi for Therapeutic Market Share by Type (2020-2025)
6.4.3 Japan Market Size by Application
6.4.3.1 Japan RNAi for Therapeutic Market Size by Application (2020-2025)
6.4.3.2 Japan RNAi for Therapeutic Market Share by Application (2020-2025)
6.4.4 Japan Market Trend and Opportunities
6.5 Australia Market: Players, Segments and Downstream
6.5.1 Australia RNAi for Therapeutic Revenue by Company (2020-2025)
6.5.2 Australia Market Size by Type
6.5.2.1 Australia RNAi for Therapeutic Market Size by Type (2020-2025)
6.5.2.2 Australia RNAi for Therapeutic Market Share by Type (2020-2025)
6.5.3 Australia Market Size by Application
6.5.3.1 Australia RNAi for Therapeutic Market Size by Application (2020-2025)
6.5.3.2 Australia RNAi for Therapeutic Market Share by Application (2020-2025)
6.5.4 Australia Market Trend and Opportunities
7 Key Players Profiles
7.1 Alnylam Pharmaceuticals
7.1.1 Alnylam Pharmaceuticals Company Details
7.1.2 Alnylam Pharmaceuticals Business Overview
7.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Introduction
7.1.4 Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)
7.1.5 Alnylam Pharmaceuticals Recent Development
7.2 Arbutus Biopharma (Tekmira)
7.2.1 Arbutus Biopharma (Tekmira) Company Details
7.2.2 Arbutus Biopharma (Tekmira) Business Overview
7.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Introduction
7.2.4 Arbutus Biopharma (Tekmira) Revenue in RNAi for Therapeutic Business (2020-2025)
7.2.5 Arbutus Biopharma (Tekmira) Recent Development
7.3 Arrowhead
7.3.1 Arrowhead Company Details
7.3.2 Arrowhead Business Overview
7.3.3 Arrowhead RNAi for Therapeutic Introduction
7.3.4 Arrowhead Revenue in RNAi for Therapeutic Business (2020-2025)
7.3.5 Arrowhead Recent Development
7.4 Dicerna Pharmaceuticals
7.4.1 Dicerna Pharmaceuticals Company Details
7.4.2 Dicerna Pharmaceuticals Business Overview
7.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Introduction
7.4.4 Dicerna Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)
7.4.5 Dicerna Pharmaceuticals Recent Development
7.5 Mirna Therapeutics
7.5.1 Mirna Therapeutics Company Details
7.5.2 Mirna Therapeutics Business Overview
7.5.3 Mirna Therapeutics RNAi for Therapeutic Introduction
7.5.4 Mirna Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025)
7.5.5 Mirna Therapeutics Recent Development
7.6 Quark Pharmaceuticals
7.6.1 Quark Pharmaceuticals Company Details
7.6.2 Quark Pharmaceuticals Business Overview
7.6.3 Quark Pharmaceuticals RNAi for Therapeutic Introduction
7.6.4 Quark Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)
7.6.5 Quark Pharmaceuticals Recent Development
7.7 RXi Pharmaceuticals
7.7.1 RXi Pharmaceuticals Company Details
7.7.2 RXi Pharmaceuticals Business Overview
7.7.3 RXi Pharmaceuticals RNAi for Therapeutic Introduction
7.7.4 RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)
7.7.5 RXi Pharmaceuticals Recent Development
7.8 Silence Therapeutics
7.8.1 Silence Therapeutics Company Details
7.8.2 Silence Therapeutics Business Overview
7.8.3 Silence Therapeutics RNAi for Therapeutic Introduction
7.8.4 Silence Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025)
7.8.5 Silence Therapeutics Recent Development
7.9 Benitec Biopharma
7.9.1 Benitec Biopharma Company Details
7.9.2 Benitec Biopharma Business Overview
7.9.3 Benitec Biopharma RNAi for Therapeutic Introduction
7.9.4 Benitec Biopharma Revenue in RNAi for Therapeutic Business (2020-2025)
7.9.5 Benitec Biopharma Recent Development
7.10 miRagen Therapeutics
7.10.1 miRagen Therapeutics Company Details
7.10.2 miRagen Therapeutics Business Overview
7.10.3 miRagen Therapeutics RNAi for Therapeutic Introduction
7.10.4 miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025)
7.10.5 miRagen Therapeutics Recent Development
7.11 Sylentis
7.11.1 Sylentis Company Details
7.11.2 Sylentis Business Overview
7.11.3 Sylentis RNAi for Therapeutic Introduction
7.11.4 Sylentis Revenue in RNAi for Therapeutic Business (2020-2025)
7.11.5 Sylentis Recent Development
7.12 Gradalis
7.12.1 Gradalis Company Details
7.12.2 Gradalis Business Overview
7.12.3 Gradalis RNAi for Therapeutic Introduction
7.12.4 Gradalis Revenue in RNAi for Therapeutic Business (2020-2025)
7.12.5 Gradalis Recent Development
7.13 Sirnaomics
7.13.1 Sirnaomics Company Details
7.13.2 Sirnaomics Business Overview
7.13.3 Sirnaomics RNAi for Therapeutic Introduction
7.13.4 Sirnaomics Revenue in RNAi for Therapeutic Business (2020-2025)
7.13.5 Sirnaomics Recent Development
7.14 Silenseed
7.14.1 Silenseed Company Details
7.14.2 Silenseed Business Overview
7.14.3 Silenseed RNAi for Therapeutic Introduction
7.14.4 Silenseed Revenue in RNAi for Therapeutic Business (2020-2025)
7.14.5 Silenseed Recent Development
8 RNAi for Therapeutic Market Dynamics
8.1 RNAi for Therapeutic Industry Trends
8.2 RNAi for Therapeutic Market Drivers
8.3 RNAi for Therapeutic Market Challenges
8.4 RNAi for Therapeutic Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Global RNAi for Therapeutic Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global RNAi for Therapeutic Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Market RNAi for Therapeutic Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global RNAi for Therapeutic Revenue (US$ Million) Market Share by Region (2020-2025)
Table 5. Global RNAi for Therapeutic Revenue Share by Region (2020-2025)
Table 6. Global RNAi for Therapeutic Revenue (US$ Million) Forecast by Region (2026-2031)
Table 7. Global RNAi for Therapeutic Revenue Share Forecast by Region (2026-2031)
Table 8. Global RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)
Table 9. Global RNAi for Therapeutic Revenue Market Share by Type (2020-2025)
Table 10. Global RNAi for Therapeutic Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 11. Global RNAi for Therapeutic Revenue Market Share by Type (2026-2031)
Table 12. Representative Players of Each Type
Table 13. Global RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)
Table 14. Global RNAi for Therapeutic Revenue Market Share by Application (2020-2025)
Table 15. Global RNAi for Therapeutic Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 16. Global RNAi for Therapeutic Revenue Market Share by Application (2026-2031)
Table 17. New Sources of Growth in RNAi for Therapeutic Application
Table 18. Global RNAi for Therapeutic Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global RNAi for Therapeutic Market Share by Players (2020-2025)
Table 20. Global Top RNAi for Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2024)
Table 21. Ranking of Global Top RNAi for Therapeutic Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by RNAi for Therapeutic Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of RNAi for Therapeutic, Headquarters and Area Served
Table 24. Global Key Players of RNAi for Therapeutic, Product and Application
Table 25. Global Key Players of RNAi for Therapeutic, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America RNAi for Therapeutic Revenue by Company (2020-2025) & (US$ Million)
Table 28. North America RNAi for Therapeutic Revenue Market Share by Company (2020-2025)
Table 29. North America RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)
Table 30. North America RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)
Table 31. Europe RNAi for Therapeutic Revenue by Company (2020-2025) & (US$ Million)
Table 32. Europe RNAi for Therapeutic Revenue Market Share by Company (2020-2025)
Table 33. Europe RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)
Table 34. Europe RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)
Table 35. China RNAi for Therapeutic Revenue by Company (2020-2025) & (US$ Million)
Table 36. China RNAi for Therapeutic Revenue Market Share by Company (2020-2025)
Table 37. China RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)
Table 38. China RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)
Table 39. Japan RNAi for Therapeutic Revenue by Company (2020-2025) & (US$ Million)
Table 40. Japan RNAi for Therapeutic Revenue Market Share by Company (2020-2025)
Table 41. Japan RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)
Table 42. Japan RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)
Table 43. Australia RNAi for Therapeutic Revenue by Company (2020-2025) & (US$ Million)
Table 44. Australia RNAi for Therapeutic Revenue Market Share by Company (2020-2025)
Table 45. Australia RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)
Table 46. Australia RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)
Table 47. Alnylam Pharmaceuticals Company Details
Table 48. Alnylam Pharmaceuticals Business Overview
Table 49. Alnylam Pharmaceuticals RNAi for Therapeutic Product
Table 50. Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 51. Alnylam Pharmaceuticals Recent Development
Table 52. Arbutus Biopharma (Tekmira) Company Details
Table 53. Arbutus Biopharma (Tekmira) Business Overview
Table 54. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product
Table 55. Arbutus Biopharma (Tekmira) Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 56. Arbutus Biopharma (Tekmira) Recent Development
Table 57. Arrowhead Company Details
Table 58. Arrowhead Business Overview
Table 59. Arrowhead RNAi for Therapeutic Product
Table 60. Arrowhead Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 61. Arrowhead Recent Development
Table 62. Dicerna Pharmaceuticals Company Details
Table 63. Dicerna Pharmaceuticals Business Overview
Table 64. Dicerna Pharmaceuticals RNAi for Therapeutic Product
Table 65. Dicerna Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 66. Dicerna Pharmaceuticals Recent Development
Table 67. Mirna Therapeutics Company Details
Table 68. Mirna Therapeutics Business Overview
Table 69. Mirna Therapeutics RNAi for Therapeutic Product
Table 70. Mirna Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 71. Mirna Therapeutics Recent Development
Table 72. Quark Pharmaceuticals Company Details
Table 73. Quark Pharmaceuticals Business Overview
Table 74. Quark Pharmaceuticals RNAi for Therapeutic Product
Table 75. Quark Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 76. Quark Pharmaceuticals Recent Development
Table 77. RXi Pharmaceuticals Company Details
Table 78. RXi Pharmaceuticals Business Overview
Table 79. RXi Pharmaceuticals RNAi for Therapeutic Product
Table 80. RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 81. RXi Pharmaceuticals Recent Development
Table 82. Silence Therapeutics Company Details
Table 83. Silence Therapeutics Business Overview
Table 84. Silence Therapeutics RNAi for Therapeutic Product
Table 85. Silence Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 86. Silence Therapeutics Recent Development
Table 87. Benitec Biopharma Company Details
Table 88. Benitec Biopharma Business Overview
Table 89. Benitec Biopharma RNAi for Therapeutic Product
Table 90. Benitec Biopharma Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 91. Benitec Biopharma Recent Development
Table 92. miRagen Therapeutics Company Details
Table 93. miRagen Therapeutics Business Overview
Table 94. miRagen Therapeutics RNAi for Therapeutic Product
Table 95. miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 96. miRagen Therapeutics Recent Development
Table 97. Sylentis Company Details
Table 98. Sylentis Business Overview
Table 99. Sylentis RNAi for Therapeutic Product
Table 100. Sylentis Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 101. Sylentis Recent Development
Table 102. Gradalis Company Details
Table 103. Gradalis Business Overview
Table 104. Gradalis RNAi for Therapeutic Product
Table 105. Gradalis Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 106. Gradalis Recent Development
Table 107. Sirnaomics Company Details
Table 108. Sirnaomics Business Overview
Table 109. Sirnaomics RNAi for Therapeutic Product
Table 110. Sirnaomics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 111. Sirnaomics Recent Development
Table 112. Silenseed Company Details
Table 113. Silenseed Business Overview
Table 114. Silenseed RNAi for Therapeutic Product
Table 115. Silenseed Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 116. Silenseed Recent Development
Table 117. RNAi for Therapeutic Market Trends
Table 118. RNAi for Therapeutic Market Drivers
Table 119. RNAi for Therapeutic Market Challenges
Table 120. RNAi for Therapeutic Market Restraints
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. RNAi for Therapeutic Product Picture
Figure 2. Global RNAi for Therapeutic Market Share by Type: 2024 VS 2031
Figure 3. siRNA Features
Figure 4. miRNA Features
Figure 5. shRNA Features
Figure 6. Global RNAi for Therapeutic Market Share by Application: 2024 VS 2031
Figure 7. Cancer
Figure 8. Cardiovascular
Figure 9. HBV
Figure 10. Others
Figure 11. RNAi for Therapeutic Report Years Considered
Figure 12. Global RNAi for Therapeutic Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global RNAi for Therapeutic Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global RNAi for Therapeutic Revenue Market Share by Region: 2020 VS 2024
Figure 15. North America RNAi for Therapeutic Revenue (US$ Million) Growth Rate (2020-2031)
Figure 16. Europe RNAi for Therapeutic Revenue (US$ Million) Growth Rate (2020-2031)
Figure 17. China RNAi for Therapeutic Revenue (US$ Million) Growth Rate (2020-2031)
Figure 18. Japan RNAi for Therapeutic Revenue (US$ Million) Growth Rate (2020-2031)
Figure 19. Australia RNAi for Therapeutic Revenue (US$ Million) Growth Rate (2020-2031)
Figure 20. Global RNAi for Therapeutic Market Share by Players in 2024
Figure 21. Global Top RNAi for Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2024)
Figure 22. The Top 10 and 5 Players Market Share by RNAi for Therapeutic Revenue in 2024
Figure 23. North America RNAi for Therapeutic Market Share by Type (2020-2025)
Figure 24. North America RNAi for Therapeutic Market Share by Application (2020-2025)
Figure 25. Europe RNAi for Therapeutic Market Share by Type (2020-2025)
Figure 26. Europe RNAi for Therapeutic Market Share by Application (2020-2025)
Figure 27. China RNAi for Therapeutic Market Share by Type (2020-2025)
Figure 28. China RNAi for Therapeutic Market Share by Application (2020-2025)
Figure 29. Japan RNAi for Therapeutic Market Share by Type (2020-2025)
Figure 30. Japan RNAi for Therapeutic Market Share by Application (2020-2025)
Figure 31. Australia RNAi for Therapeutic Market Share by Type (2020-2025)
Figure 32. Australia RNAi for Therapeutic Market Share by Application (2020-2025)
Figure 33. Alnylam Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 34. Arbutus Biopharma (Tekmira) Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 35. Arrowhead Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 36. Dicerna Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 37. Mirna Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 38. Quark Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 39. RXi Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 40. Silence Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 41. Benitec Biopharma Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 42. miRagen Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 43. Sylentis Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 44. Gradalis Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 45. Sirnaomics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 46. Silenseed Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 47. Bottom-up and Top-down Approaches for This Report
Figure 48. Data Triangulation
Figure 49. Key Executives Interviewed
Table 1. Global RNAi for Therapeutic Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global RNAi for Therapeutic Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Market RNAi for Therapeutic Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global RNAi for Therapeutic Revenue (US$ Million) Market Share by Region (2020-2025)
Table 5. Global RNAi for Therapeutic Revenue Share by Region (2020-2025)
Table 6. Global RNAi for Therapeutic Revenue (US$ Million) Forecast by Region (2026-2031)
Table 7. Global RNAi for Therapeutic Revenue Share Forecast by Region (2026-2031)
Table 8. Global RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)
Table 9. Global RNAi for Therapeutic Revenue Market Share by Type (2020-2025)
Table 10. Global RNAi for Therapeutic Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 11. Global RNAi for Therapeutic Revenue Market Share by Type (2026-2031)
Table 12. Representative Players of Each Type
Table 13. Global RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)
Table 14. Global RNAi for Therapeutic Revenue Market Share by Application (2020-2025)
Table 15. Global RNAi for Therapeutic Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 16. Global RNAi for Therapeutic Revenue Market Share by Application (2026-2031)
Table 17. New Sources of Growth in RNAi for Therapeutic Application
Table 18. Global RNAi for Therapeutic Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global RNAi for Therapeutic Market Share by Players (2020-2025)
Table 20. Global Top RNAi for Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2024)
Table 21. Ranking of Global Top RNAi for Therapeutic Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by RNAi for Therapeutic Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of RNAi for Therapeutic, Headquarters and Area Served
Table 24. Global Key Players of RNAi for Therapeutic, Product and Application
Table 25. Global Key Players of RNAi for Therapeutic, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America RNAi for Therapeutic Revenue by Company (2020-2025) & (US$ Million)
Table 28. North America RNAi for Therapeutic Revenue Market Share by Company (2020-2025)
Table 29. North America RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)
Table 30. North America RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)
Table 31. Europe RNAi for Therapeutic Revenue by Company (2020-2025) & (US$ Million)
Table 32. Europe RNAi for Therapeutic Revenue Market Share by Company (2020-2025)
Table 33. Europe RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)
Table 34. Europe RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)
Table 35. China RNAi for Therapeutic Revenue by Company (2020-2025) & (US$ Million)
Table 36. China RNAi for Therapeutic Revenue Market Share by Company (2020-2025)
Table 37. China RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)
Table 38. China RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)
Table 39. Japan RNAi for Therapeutic Revenue by Company (2020-2025) & (US$ Million)
Table 40. Japan RNAi for Therapeutic Revenue Market Share by Company (2020-2025)
Table 41. Japan RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)
Table 42. Japan RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)
Table 43. Australia RNAi for Therapeutic Revenue by Company (2020-2025) & (US$ Million)
Table 44. Australia RNAi for Therapeutic Revenue Market Share by Company (2020-2025)
Table 45. Australia RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)
Table 46. Australia RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)
Table 47. Alnylam Pharmaceuticals Company Details
Table 48. Alnylam Pharmaceuticals Business Overview
Table 49. Alnylam Pharmaceuticals RNAi for Therapeutic Product
Table 50. Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 51. Alnylam Pharmaceuticals Recent Development
Table 52. Arbutus Biopharma (Tekmira) Company Details
Table 53. Arbutus Biopharma (Tekmira) Business Overview
Table 54. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product
Table 55. Arbutus Biopharma (Tekmira) Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 56. Arbutus Biopharma (Tekmira) Recent Development
Table 57. Arrowhead Company Details
Table 58. Arrowhead Business Overview
Table 59. Arrowhead RNAi for Therapeutic Product
Table 60. Arrowhead Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 61. Arrowhead Recent Development
Table 62. Dicerna Pharmaceuticals Company Details
Table 63. Dicerna Pharmaceuticals Business Overview
Table 64. Dicerna Pharmaceuticals RNAi for Therapeutic Product
Table 65. Dicerna Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 66. Dicerna Pharmaceuticals Recent Development
Table 67. Mirna Therapeutics Company Details
Table 68. Mirna Therapeutics Business Overview
Table 69. Mirna Therapeutics RNAi for Therapeutic Product
Table 70. Mirna Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 71. Mirna Therapeutics Recent Development
Table 72. Quark Pharmaceuticals Company Details
Table 73. Quark Pharmaceuticals Business Overview
Table 74. Quark Pharmaceuticals RNAi for Therapeutic Product
Table 75. Quark Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 76. Quark Pharmaceuticals Recent Development
Table 77. RXi Pharmaceuticals Company Details
Table 78. RXi Pharmaceuticals Business Overview
Table 79. RXi Pharmaceuticals RNAi for Therapeutic Product
Table 80. RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 81. RXi Pharmaceuticals Recent Development
Table 82. Silence Therapeutics Company Details
Table 83. Silence Therapeutics Business Overview
Table 84. Silence Therapeutics RNAi for Therapeutic Product
Table 85. Silence Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 86. Silence Therapeutics Recent Development
Table 87. Benitec Biopharma Company Details
Table 88. Benitec Biopharma Business Overview
Table 89. Benitec Biopharma RNAi for Therapeutic Product
Table 90. Benitec Biopharma Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 91. Benitec Biopharma Recent Development
Table 92. miRagen Therapeutics Company Details
Table 93. miRagen Therapeutics Business Overview
Table 94. miRagen Therapeutics RNAi for Therapeutic Product
Table 95. miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 96. miRagen Therapeutics Recent Development
Table 97. Sylentis Company Details
Table 98. Sylentis Business Overview
Table 99. Sylentis RNAi for Therapeutic Product
Table 100. Sylentis Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 101. Sylentis Recent Development
Table 102. Gradalis Company Details
Table 103. Gradalis Business Overview
Table 104. Gradalis RNAi for Therapeutic Product
Table 105. Gradalis Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 106. Gradalis Recent Development
Table 107. Sirnaomics Company Details
Table 108. Sirnaomics Business Overview
Table 109. Sirnaomics RNAi for Therapeutic Product
Table 110. Sirnaomics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 111. Sirnaomics Recent Development
Table 112. Silenseed Company Details
Table 113. Silenseed Business Overview
Table 114. Silenseed RNAi for Therapeutic Product
Table 115. Silenseed Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)
Table 116. Silenseed Recent Development
Table 117. RNAi for Therapeutic Market Trends
Table 118. RNAi for Therapeutic Market Drivers
Table 119. RNAi for Therapeutic Market Challenges
Table 120. RNAi for Therapeutic Market Restraints
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. RNAi for Therapeutic Product Picture
Figure 2. Global RNAi for Therapeutic Market Share by Type: 2024 VS 2031
Figure 3. siRNA Features
Figure 4. miRNA Features
Figure 5. shRNA Features
Figure 6. Global RNAi for Therapeutic Market Share by Application: 2024 VS 2031
Figure 7. Cancer
Figure 8. Cardiovascular
Figure 9. HBV
Figure 10. Others
Figure 11. RNAi for Therapeutic Report Years Considered
Figure 12. Global RNAi for Therapeutic Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global RNAi for Therapeutic Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global RNAi for Therapeutic Revenue Market Share by Region: 2020 VS 2024
Figure 15. North America RNAi for Therapeutic Revenue (US$ Million) Growth Rate (2020-2031)
Figure 16. Europe RNAi for Therapeutic Revenue (US$ Million) Growth Rate (2020-2031)
Figure 17. China RNAi for Therapeutic Revenue (US$ Million) Growth Rate (2020-2031)
Figure 18. Japan RNAi for Therapeutic Revenue (US$ Million) Growth Rate (2020-2031)
Figure 19. Australia RNAi for Therapeutic Revenue (US$ Million) Growth Rate (2020-2031)
Figure 20. Global RNAi for Therapeutic Market Share by Players in 2024
Figure 21. Global Top RNAi for Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2024)
Figure 22. The Top 10 and 5 Players Market Share by RNAi for Therapeutic Revenue in 2024
Figure 23. North America RNAi for Therapeutic Market Share by Type (2020-2025)
Figure 24. North America RNAi for Therapeutic Market Share by Application (2020-2025)
Figure 25. Europe RNAi for Therapeutic Market Share by Type (2020-2025)
Figure 26. Europe RNAi for Therapeutic Market Share by Application (2020-2025)
Figure 27. China RNAi for Therapeutic Market Share by Type (2020-2025)
Figure 28. China RNAi for Therapeutic Market Share by Application (2020-2025)
Figure 29. Japan RNAi for Therapeutic Market Share by Type (2020-2025)
Figure 30. Japan RNAi for Therapeutic Market Share by Application (2020-2025)
Figure 31. Australia RNAi for Therapeutic Market Share by Type (2020-2025)
Figure 32. Australia RNAi for Therapeutic Market Share by Application (2020-2025)
Figure 33. Alnylam Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 34. Arbutus Biopharma (Tekmira) Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 35. Arrowhead Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 36. Dicerna Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 37. Mirna Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 38. Quark Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 39. RXi Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 40. Silence Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 41. Benitec Biopharma Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 42. miRagen Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 43. Sylentis Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 44. Gradalis Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 45. Sirnaomics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 46. Silenseed Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)
Figure 47. Bottom-up and Top-down Approaches for This Report
Figure 48. Data Triangulation
Figure 49. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Oral Antianginal Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Polyester BCF Yarns Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Glass Mat Reinforced Thermoplastics (GMT) for Automotive Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232